About the job

We are seeking a preclinical/translational pharmacologist with experience in developing oncology small-molecule therapeutics. The ideal candidate would have solid experience in designing and conducting preclinical/translational pharmacology studies and be knowledgeable in molecular pathways involved in cell death and survival and experienced in conducting studies to elucidate the mechanisms of action of drug candidates. Prior experience in contributing to INDs and leading IND-enabling preclinical programs is highly desirable. You will conduct research to advance small-molecule therapeutics that work through novel ferroptosis mechanisms, and you will also be able to collaborate and communicate with medicinal chemists, biologists, DMPK and biomarker scientists, and nuclear medicine specialists to enable integration of knowledge across functions to effectively advance our pipeline.

The ideal candidate for this role will have demonstrated success in these responsibilities:

  • Interfacing with biologists, chemists, and DMPK scientists to design and conduct preclinical pharmacology studies as part of a project team, incorporating appropriate PK/PD and biomarker assessments as necessary at the appropriate stage of the program to enable development candidate selection and IND preparation, and to inform early clinical development.
  • Designing, conducting, and overseeing the execution of in vivo pharmacology and efficacy studies to support the IND (both in-house and at CROs). Providing oversight to a small team of scientists who are involved in conducting these studies.
  • Serving as the primary lead for IND enabling pharmacology package and working in collaboration with other project team members.
  • Help manage day-to-day operations of pharmacology lab and vivarium.
  • Initiating collaborations with external KOLs/ leaders in the field to generate human translational evidence to support the clinical programs.
  • Working with internal and external collaborators for indication expansion, collaborating with team members to generate data from preclinical studies to inform subsequent clinical development.
  • Authoring appropriate sections of regulatory documents and review documents such as IND, IB, CSRs.
  • Providing input into appropriate sections of clinical-protocol design, providing input to clinical development plan, and serving as member of clinical sub-team when needed.
  • Developing and providing input into biomarker strategy to enable successful clinical development as a part of the IDP including biomarkers to assess target engagement, pharmacodynamics, disease biomarkers and novel endpoints as appropriate for indication.   • Incorporating metabolic imaging studies (e.g., PET/SPECT, MRI/MRS) into preclinical and clinical programs.